Trials / Conditions / Stage III Bladder Cancer

Stage III Bladder Cancer

24 registered clinical trials studyying Stage III Bladder Cancer.

Status	Trial	Sponsor	Phase
Completed	Ask Questions (ASQ):Implementation of a Communication Intervention NCT05025748	Barbara Ann Karmanos Cancer Institute	N/A
Completed	Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278	Rutgers, The State University of New Jersey	Phase 1
Terminated	Afatinib in Advanced Refractory Urothelial Cancer NCT02122172	University of Chicago	Phase 2
Terminated	MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Wi NCT02735512	University of Southern California	—
Completed	Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319	Mayo Clinic	EARLY_Phase 1
Terminated	Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urotheli NCT02316548	NRG Oncology	Phase 2
Completed	Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer NCT01938573	University of Washington	Phase 1 / Phase 2
Completed	Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520	City of Hope Medical Center	N/A
Terminated	Adjuvant Radiation for High Risk Bladder Cancer NCT01954173	Emory University	N/A
Withdrawn	Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and NCT01639521	University of Southern California	Phase 2
Terminated	Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cance NCT01611662	Fox Chase Cancer Center	Phase 2
Terminated	Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder NCT01382706	University of Southern California	Phase 2
Terminated	Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333	National Cancer Institute (NCI)	Phase 1
Completed	Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer NCT00666562	National Cancer Institute (NCI)	Phase 2
Completed	Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Functi NCT00478361	M.D. Anderson Cancer Center	Phase 2
Completed	VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium NCT00407485	National Cancer Institute (NCI)	Phase 2
Terminated	Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium NCT00112905	National Cancer Institute (NCI)	Phase 2
Completed	Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract NCT00112671	National Cancer Institute (NCI)	Phase 2
Completed	Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transition NCT00072150	National Cancer Institute (NCI)	Phase 2
Terminated	Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystec NCT00072137	National Cancer Institute (NCI)	Phase 1
Completed	Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cy NCT00028756	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3
Completed	Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer NCT00021099	National Cancer Institute (NCI)	Phase 2
Completed	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074	National Cancer Institute (NCI)	Phase 1
Completed	Gene Therapy in Treating Patients With Advanced Bladder Cancer NCT00003167	National Cancer Institute (NCI)	Phase 1